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Abstract
This article presents a review of the literature on hepatic resection for the treatment of liver metastases in gastric carcinoma,
and discusses the indications, mortality rates, prognostic factors and long-term results. Reports on hepatectomy for liver
metastases from gastric cancer are rare, the results are disappointing, and further studies are required.
Background
The efficacy of resection of liver metastases from
colorectal and neuroendocrine tumors has been
established [1,2]. In contrast, reports of hepatic
resection for liver metastases from gastric cancer
are rare, and the indications for hepatic resection
of metastases from gastric cancer have not been
established. Several authors have reported on hepa-
tectomy of liver metastases from gastric cancer in a
small number of the patients [3/14]. The long-term
results after hepatic resection are disappointing,
although long-term survivors after hepatectomy do
exist. Baba et al. [15] have shown that the outcome
for patients with non-curative resection for advanced
gastric cancer is extremely poor. Therefore, the
determination of selection criteria for hepatic resec-
tion and conditions for long-term survival after
hepatectomy for metastases from gastric cancer is
crucial. To our knowledge, 12 studies of hepatic
resection for metastatic gastric carcinoma have
been published [3/14]. The number of patients in
these 12 reports varied from 11 to 40, and the
total number of patients was 229. These reports on
the results of hepatectomy for metastases of gastric
cancer are reviewed here.
Indications
As noted before, the indications for hepatic resection
for metastases have not been established. The criteria
for hepatic resection offered by Okano et al. [11]
are broadly defined: hepatic resection is indicated
in patients (1) with synchronous metastases who have
no peritoneal dissemination or other distant metas-
tases and (2) with metachronous metastases, but
no other recurrent lesion. Ambiru et al. [8] added a
third criterion, i.e. complete resection of hepatic
metastases with acceptable postoperative hepatic
function. In a recent report by Roh et al. [14], hepatic
resection is said to be indicated only in patients
with hepatic metastases in one lobe of the liver
without peritoneal dissemination, hilar node metas-
tases or distant metastases. Below, we examine prog-
nostic factors and discuss the significance of these
criteria.
Although the liver is a frequent location of metas-
tases from gastric cancer, hepatic resection is seldom
indicated for metastatic gastric cancer because of
multiple hepatic nodules or associated peritoneal
dissemination. Ochiai et al. [3] found a hepatic
resection incidence of 21 in 6540 patients (0.3%)
with a gastric cancer who underwent a gastrectomy.
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Saiura et al. [10] found an incidence of 10 in 1807
similar patients (0.6%), and Okano et al. [11] found
an incidence of 19 in 807 patients (2.4%).
Mortality and long-term results
Mortality after hepatic resection cannot be ignored. In
the 12 reports reviewed here, 6 of 229 patients (2.6%)
died in hospital after hepatic resection. Zacherl et al.
[9] suggested that the in-hospital mortality rate
might be higher in patients who underwent synchro-
nous hepatic resection than in those who under
went metachronous hepatic resection. In 12 reports
[3/14], three of four hepatic resection patients
who died in hospital and had detailed documenta-
tion, underwent synchronous hepatic resection.
Careful patient selection may be necessary, espe-
cially in the patients with synchronous hepatic
metastases from gastric cancer. Also, synchro-
nous hepatectomy should be performed only in
high volume centres, where procedural risk will
probably be lower.
The long-term results of hepatic resection are
unsatisfactory. In the 12 studies cited above, the
1-year survival rate ranged from 42% to 90% and
the 5-year survival rate from 0% to 38% (Table I).
More than 50% of patients who underwent a hepatic
resection died within 2 years after hepatectomy
and only a small number of the patients survived
more than 5 years after hepatectomy. The total
number of 5-year survivors was 25 of 229 patients
(11%). Therefore, it is essential to clarify the
condition of 5-year survivors. At the same time,
because these data are based on patients who under-
went complete resection, incomplete resection is
a contraindication for hepatectomy. Otherwise,
Imamura et al. [7] found that all patients
with extrahepatic distant metastasis died within
1 year after hepatectomy. The presence of extrahepa-
tic distant metastasis is also a contraindication for
hepatectomy.
Prognostic factors
Prognostic factors were reported in the eight papers
[3,4,7/9,11/13] in which the number of the patients
were at least 15 and all patients underwent a curative
resection without remnant cancer. The number of the
metastatic nodules in the liver has been reported to be
an important prognostic factor in six [4,9,11/13] of
eight studies. In four papers [4,9,11,13], solitary
tumour was a significant good prognostic factor, and
in one paper [12], the presence of no more than
3 nodules was a significant good predictor. In one
paper [8], although unilobular distribution of
liver nodules was a good predictor, most of the
unilobular tumours were solitary. Regarding the
primary gastric cancer, Ochiai et al. [4] and our
previous study [12] revealed that the presence of
microscopic lymphatic and venous invasion in the
primary gastric cancer was a significant poor prog-
nostic factor. However, some studies showed these
were not significant prognostic factors [4] and are still
controversial.
Timing of hepatic resection has been reported to
be a significant prognostic factor. In three [8,9,11]
of eight studies, synchronous hepatectomy was a
significant poor prognostic factor. Nevertheless, as
discussed below, analysis showed that 11 of 24 5-year
survivors underwent a synchronous hepatectomy.
Thus, synchronous hepatectomy should not be a
contraindication for hepatic resection. Surgical
margin /10 mm in hepatic resection was a good
prognostic factor in two papers [8,11]. These are still
controversial even in colorectal cancer and further
study is necessary. As mentioned earlier, the number
Table I. The short- and long-term results of hepatectomy for gastric metastases.
Authors [Ref.] Year n Median Mean 1-year 3-year 5-year In-hospital mortality 5-year survival
Ochiai et al. [3] 1994 21 0 4 (19%)
Miyazaki et al. [4] 1997 21 11 27 42 21 21 0 2 (10%)
Elias et al. [5] 1998 11 90 35
Fujii et al. [6] 2001 10 16 37 60 20 20 1 1 (10%)
Imamura et al. [7] 2001 17 47 22 0 0 0
Ambiru et al. [8] 2001 40 18 0 6 (15%)
Zacherl et al. [9] 2002 15 9 16 0 0
Saiura et al. [10] 2002 10 25 27 50 30 20 2 2 (20%)
Okano et al. [11] 2002 19 77 34 34 0 4 (21%)
Shirabe et al. [12] 2003 36 64 26 26 0 4 (11%)
Sakamoto et al. [13] 2003 26 21 73 38 38 1 1 (4%)
Roh et al. [14] 2005 11 13 33 42 21 21 0 2 (18%)
Sum 216 24 (11%)
Two reports by Miyazaki et al. and Ambiru et al. are from same institute. The data from Miyazaki et al. are included in the series of Ambiru
et al. Nevertheless, some data such as 5-year survivors are described in Miyazaki et al. Then, we used both data, but data from Miyazaki
et al. are excluded from the total number of the patients and 5-year survivors. Median/median survival of the patients (months);
mean/mean survival of the patients (months); 1-year, 3-year, and 5 year are 1-year, 3-year and 5-year survival rates (%).
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of 5-year survivors after hepatectomy was 25. Most of
these studies offered detailed data on these long-term
survivors (summarized in Table II). Seventeen of 19
long-term survivors (89.5%) had only one liver
nodule. Of the remaining 2 long-term survivors, one
had 3 hepatic nodules and the other patient had
10 nodules. These multiple nodules were unilobular
in both patients. Thus, the number of hepatic
metastases was still an important factor. As for timing
of hepatectomy, 11 of 24 long-term survivors
had undergone synchronous hepatectomy. Thus,
synchronous hepatectomy was not a contraindication.
The mean diameter of hepatic nodules was 3.5 cm
in 12 long-term survivors. As for the primary
gastric cancer, their UICC (International Union
Against Cancer) classification varied from T2 to T4.
Lymph node metastases were observed in 15 of 18
patients (83%).
Recurrence
Recurrence after hepatectomy was usually in the liver
[8,12]. The incidence of intrahepatic recurrence
ranged from 47% to 73%. Although no papers
in this series [3/14] have proven the efficacy of
adjuvant chemotherapy, aggressive hepatic artery
infusion chemotherapy might improve survival after
hepatic resection [15/17]. Further investigation is
necessary.
Conclusion
In conclusion, the results of hepatectomy for liver
metastases from gastric cancer are disappointing.
More than half of the patients who underwent
hepatectomy died of recurrence and only 11% of
patients survived more than 5 years after hepatect-
omy. Thus, hepatectomy for liver metastases should
be performed only in carefully selected cases. At
present, the criteria for hepatic resection can be
defined as follows: (1) patients with synchronous
metastases who have no peritoneal dissemination or
other distant metastases; (2) patients with metachro-
nous metastases who have no other recurrent lesions;
(3) complete resection of hepatic metastases with an
acceptable postoperative hepatic function; (4) regard-
less of the timing of hepatic resection; (5) solitary liver
metastasis. Other prognostic factors, such as surgical
margin /10 mm, lymphatic and venous invasion of
the primary gastric cancer cannot be determined
in this series of articles. Further examination is
necessary.
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